

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification⁷: C07K 7/23, A61K 38/09	A1	(11) International publication number: WO 00/55190 (43) International publication date: 21 September 2000 (21.09.00)
(21) International application number: PCT/EP00/02165 (22) International filing date: 11 March 2000 (11.03.00) (30) Data relating to the priority: 199 11 771.3 17 March 1999 (17.03.99) DE (71) Applicant: ASTA MEDICA AG [DE/DE]; An der Pikardie 10, D-01277 Dresden (DE). (72) Inventors: BERND, Michael; Günthersburgallee 52, D-60316 Frankfurt (DE). KUTSCHER, Bernhard; Stresemannstrasse 9, D-63477 Maintal (DE). GÜNTHER, Eckhard; Wingertstrasse 176, D-63477 Maintal (DE). ROMEIS, Peter; Mühlrainstrasse 16, D-63571 Gelnhausen (DE). REISSMANN, Thomas; Massbornstrasse 44, D-60437 Frankfurt (DE). BECKERS, Thomas; Passavantstrasse 26, D-60596 Frankfurt (DE).		(81) Designated states: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With the International Search Report.
As printed (54) Title: NOVEL LHRH ANTAGONISTS WITH IMPROVED SOLUBILITY CHARACTERISTICS (54) Bezeichnung: NEUE LHRH-ANTAGONISTEN MIT VERBESSERTEN LÖSLICHKEITSEIGENSCHAFTEN (57) Abstract The invention relates to peptides which contain N-methylated amino acid building blocks and are provided with improved water solubility. Medicaments containing the inventive peptides can be used for the treatment of hormone-dependent tumours and hormone-influenced, non-malignant diseases. (57) Zusammenfassung Die Erfindung betrifft Peptide, die N-methylierte Aminosäurebausteine enthalten und eine verbesserte Wasserlöslichkeit aufweisen. Arzneimittel, in denen die erfindungsgemässen Peptide enthalten sind, können zur Behandlung hormonabhängiger Tumore und hormonbeeinflusster nicht-maligner Erkrankungen verwendet werden.		